Blueprint Medicines Co. (NASDAQ:BPMC) is DAFNA Capital Management LLC's 10th Largest Position

DAFNA Capital Management LLC boosted its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 23.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 149,763 shares of the biotechnology company's stock after buying an additional 28,000 shares during the period. Blueprint Medicines makes up approximately 3.3% of DAFNA Capital Management LLC's investment portfolio, making the stock its 10th largest holding. DAFNA Capital Management LLC owned 0.24% of Blueprint Medicines worth $13,062,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Torray Investment Partners LLC boosted its position in shares of Blueprint Medicines by 1.1% in the 4th quarter. Torray Investment Partners LLC now owns 16,499 shares of the biotechnology company's stock worth $1,439,000 after buying an additional 186 shares in the last quarter. Franklin Resources Inc. increased its stake in Blueprint Medicines by 0.7% during the third quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company's stock valued at $3,259,000 after purchasing an additional 265 shares during the last quarter. Summit Investment Advisors Inc. increased its position in Blueprint Medicines by 4.4% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,652 shares of the biotechnology company's stock worth $580,000 after buying an additional 283 shares during the period. Pitcairn Co. increased its stake in shares of Blueprint Medicines by 2.8% during the fourth quarter. Pitcairn Co. now owns 10,608 shares of the biotechnology company's stock valued at $925,000 after acquiring an additional 293 shares during the period. Finally, Hillsdale Investment Management Inc. boosted its holdings in Blueprint Medicines by 0.6% during the fourth quarter. Hillsdale Investment Management Inc. now owns 50,830 shares of the biotechnology company's stock worth $4,433,000 after buying an additional 310 shares in the last quarter.

Analyst Upgrades and Downgrades

BPMC has been the subject of several recent analyst reports. Morgan Stanley assumed coverage on Blueprint Medicines in a research note on Thursday, March 20th. They set an "equal weight" rating and a $100.00 price target for the company. Piper Sandler raised their target price on shares of Blueprint Medicines from $109.00 to $119.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. HC Wainwright reaffirmed a "buy" rating and issued a $135.00 price objective on shares of Blueprint Medicines in a report on Friday, May 2nd. Scotiabank began coverage on shares of Blueprint Medicines in a report on Friday, March 7th. They issued a "sector outperform" rating and a $150.00 target price on the stock. Finally, JPMorgan Chase & Co. boosted their target price on shares of Blueprint Medicines from $126.00 to $129.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $126.56.

Blueprint Medicines Stock Performance

BPMC stock traded down $0.80 during midday trading on Tuesday, hitting $99.51. 312,240 shares of the company traded hands, compared to its average volume of 778,688. The business has a 50 day simple moving average of $88.70 and a 200-day simple moving average of $94.01. Blueprint Medicines Co. has a twelve month low of $73.04 and a twelve month high of $121.90. The stock has a market capitalization of $6.43 billion, a price-to-earnings ratio of -92.14 and a beta of 0.83. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.32). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. The firm had revenue of $149.41 million for the quarter, compared to the consensus estimate of $158.31 million. During the same quarter in the previous year, the firm earned $1.40 EPS. The company's revenue was up 55.5% compared to the same quarter last year. As a group, equities research analysts predict that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

Insider Transactions at Blueprint Medicines

In other Blueprint Medicines news, insider Ariel Hurley sold 3,203 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $92.62, for a total transaction of $296,661.86. Following the transaction, the insider now owns 18,270 shares in the company, valued at approximately $1,692,167.40. This represents a 14.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Christina Rossi sold 2,274 shares of the business's stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $101.75, for a total transaction of $231,379.50. Following the transaction, the chief operating officer now owns 66,992 shares in the company, valued at approximately $6,816,436. This trade represents a 3.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,503 shares of company stock valued at $1,027,931. Company insiders own 4.21% of the company's stock.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.